Q32 Bio Inc. (QTTB)
| Previous close | 18.05 |
| Open | 18.25 |
| Bid | 16.82 x 100 |
| Ask | 17.58 x 100 |
| Day's range | 16.86 - 18.97 |
| 52-week range | 8.24 - 32.88 |
| Volume | |
| Avg. volume | 62,720 |
| Market cap | 206.957M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Q32 Bio Joins Russell 3000® Index
Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that the company is joining the broad-market Russell 3000® Index at the conclusion of the 2024 Russell Indexes annual reconstitution, effective upon the U.S. market opening today, July 1, 2024.
- PR Newswire
Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today reported financial results for the quarter ended March 31, 2024 and provided recent corporate updates.
- PR Newswire
Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer
Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Lee Kalowski as President and Chief Financial Officer. Mr. Kalowski brings over 20 years of biopharmaceutical experience with a focus on strategy, raising capital, and financial operations.
